K

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Associate Director - Analytical Development and Quality Control

Bioprocess & Biomanufacturing +1Confirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A bachelor's degree and 10+ years of pharmaceutical or biotech industry experience, including late-phase drug substance development, NDA submissions, PAI readiness, and commercial launch in accordance with global CMC regulatory filings; alternatively, an advanced degree with 5+ years of experience.
  • Knowledge of peptide chemistry, peptide degradation pathways, and impurity control strategy; experience supporting drug substance PPQ or process validation analytically.
  • Demonstrated analytical project leadership and cross-functional team participation.
  • Experience setting commercial specifications.
  • Experience authoring regulatory documents, including NDA experience.
  • Knowledge of drug development activities relating to cGMP, quality systems, global regulatory requirements, and USP, EP, JP, and CHP requirements.
  • Strong understanding of applicable ICH guidelines.
  • Method validation experience.
  • Experience overseeing analytical activities at CDMOs and/or CTLs.
  • Ability to make technically driven decisions and solve problems.
  • Effective written and verbal communication and interpersonal skills.
  • A bachelor's degree with 10+ years or an advanced degree with 5+ years of relevant experience.
  • A degree in Analytical Chemistry, Organic Chemistry, Physical Chemistry, Pharmaceutical Sciences, or a closely related field.
  • Willingness to travel to domestic and international destinations as needed.
  • Ability to work in environments that may have specific gowning or dress code requirements on rare occasions.

Responsibilities

  • Lead analytical development and support QC activities related to the development and commercialization of peptide drug substances.
  • Develop and maintain current knowledge of analytical methods and product and process control strategies supporting peptide drug substances.
  • Lead development of analytical methods through the external network to support the product pipeline, including analytical transfers and troubleshooting in CDMO laboratories.
  • Provide input into analytical development strategies and manage execution of functional activities supporting clinical development, regulatory filings (IND/NDA/MAA), product approvals, and commercialization.
  • Author relevant CMC sections for global regulatory filings.
  • Participate on cross-functional CMC teams for assigned projects to support adequate development and execution of CMC plans and strategies.
  • Communicate CMC project status to cross-functional stakeholders and assist in driving decision-making.
  • Collaborate with cross-functional line functions to ensure CMC and program goals are met.
  • Travel to CDMOs and other service providers as needed to oversee vendor technology transfers and analytical activities.

Desired Qualifications

  • Knowledge and experience in analytical development of injectable products and associated control strategies.
  • Knowledge and experience in analytical development of small molecules and solid oral dosage forms.
  • Successful support of at least one NDA and commercial launch.
  • Synthetic peptide manufacturing knowledge.
  • Experience with statistics and applying statistics to analytical chemistry.
  • Regulatory inspection experience.

About the Company

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Kailera Therapeutics focuses on obesity and related metabolic conditions by acquiring and developing clinical-stage drug candidates and moving them toward commercialization. Its lead asset, KAI-9531, is an injectable dual agonist of GLP-1 and GIP receptors for obesity and type 2 diabetes, and the pipeline includes an oral GLP-1 agonist (KAI-7535), an oral tablet form of KAI-9531, and an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors (KAI-4729). The company differentiates itself by sourcing assets outside of early research, pursuing a mix of injectable and oral therapies, and leveraging a high-profile leadership team and substantial funding to progress a broad portfolio under external licenses. Kailera’s goal is to advance multiple metabolic disease therapies from clinical development toward commercialization to improve outcomes for patients with obesity and related conditions.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Kailera Therapeutics

See more jobs